5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund

Page 1 of 5

Below is the list of 5 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund. For a detailed analysis and Mark Lampert’s investment philosophy, you can directly jump to 10 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund.

5. Merus N.V. (NASDAQ:MRUS)

Biotechnology Value Fund’s Stake Value: $153 million

Percentage of Biotechnology Value Fund’s 13F Portfolio: 5.75% 

Number of Hedge Fund Holders: 23

Merus N.V. (NASDAQ:MRUS) is the long-running stock holding of Mark Lampert’s fund. The fund first initiated a position in the pharma stock in the first quarter of 2019. At the end of the June quarter, BVF held 7.3 million shares of Merus, representing 18.8% of the ownership in the company.  

Page 1 of 5